Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement |
| July 15, 2020 | July 2020 Bond Updates |
|
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in... |
| View more at: https://www.prnewswire.com:443/news-releases/samsung-biologics-and-immuneoncia-sign-multi-product-development-and-manufacturing-agreement-301093634.html |
| Related News |